The FDA has approved Pfizer’s pegfilgrastim biosimilar Nyvepria for use in lowering the incidence of infection as manifested by febrile neutropenia.
The FDA has approved Pfizer’s pegfilgrastim biosimilar Nyvepria for use in lowering the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.
There are 3 pegfilgrastim products already on the US market that also reference Amgen’s Neulasta. Those include Ziextenzo, Udenyca, and Fulphila.
Pfizer intends to launch Nyvepria on the US market later this year. No specific date was provided.
“The FDA approval of Nyvepria is a positive step that could both enable cost savings and increase access to an important treatment option,” said Andy Schmeltz, global president of Pfizer Oncology, in a statement.
“Chemotherapy-induced febrile neutropenia is a relatively common and severe [adverse] effect of some cancer treatments that could cause significant complications and can result in the alteration of treatment regimens,” said Ali McBride, PharmD, MS, BCPS, BCOP, immediate past president of the Association of Community Cancer Centers. “The FDA approval of Nyvepria provides clinicians with an additional long-acting treatment option that can help prevent infections in patients undergoing myelosuppressive chemotherapy.”
Pfizer now has 6 FDA-approved oncology biosimilars, 3 of which are indicated for supportive care for patients with cancer. Its total US-approved biosimilar portfolio, including the cancer agents, includes 9 biosimilars.
Pfizer's biosimilar engine has been active in the United States so far in 2020. The company brought a rituximab biosimilar (Ruxience) to market earlier this year, along with a trastuzumab (Trazimera).
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.